GHK-Cu peptide guide

GHK-Cu is a small peptide complex made of three amino acids: glycine, histidine, and lysine, bound to a copper(II) ion. On cosmetic ingredient labels you'll see it written as Copper Tripeptide-1. The GHK peptide was first isolated from human blood plasma by Loren Pickart in 1973, who initially described it as a factor that pushed older liver tissue toward a more youthful repair pattern.

GHK is naturally present in human plasma, saliva, and urine. Published reviews report that plasma levels decline meaningfully with age; older adults carry roughly half the GHK that younger adults do. That decline is part of why the peptide gets framed as a regenerative or restorative compound, but a natural decline alone is not evidence that supplementation reverses it in humans, and that distinction is worth holding onto when reading marketing copy.

The strongest evidence for GHK-Cu is in topical cosmetic use. A 2018 review (Pickart & Margolina, International Journal of Molecular Sciences) summarizes the supporting clinical work, including a controlled trial in 71 women with mild-to-advanced photoaging where a daily GHK-Cu facial cream improved skin density, thickness, and wrinkle appearance over three months versus placebo, and a 41-woman eye-cream trial that outperformed both placebo and a vitamin K cream on periorbital wrinkling and skin density. A more recent March 2026 review in Systems Microbiology and Biomanufacturing (Lu et al.) catalogs the molecular mechanisms and emerging biomanufacturing methods. This is useful context for how the compound is now produced at scale, but not new clinical data.

For hair, the human evidence is thinner. The most-cited preclinical work is a 2024 Bioactive Materials paper (Liu et al.) using an ionic-liquid microemulsion delivery system in mice, which reported that copper peptide formulation initiated the anagen growth phase faster than 5% minoxidil in that model. Earlier work by Pyo et al. (2007) on a related copper peptide (AHK-Cu) showed proliferation of human dermal papilla cells ex vivo at nanomolar concentrations. Mechanistically the case for hair is interesting; clinically it is still mostly extrapolation from animal and ex vivo data.

For wound healing, anti-inflammatory, and pulmonary fibrosis applications, the evidence is largely animal-model and in vitro. A 2020 study in Life Sciences (Ma et al.) reported that GHK-Cu reduced bleomycin-induced pulmonary fibrosis in mice via anti-oxidative and anti-inflammatory pathways. These are interesting mechanistic signals but should not be read as established clinical effects in humans.

I verified the human-trial sample sizes against the source citations in the Pickart & Margolina 2018 review directly, and the published-review tone is consistently more conservative than the way these results get summarized in supplier marketing. That is worth keeping in mind when reading product copy.

GHK-Cu shows up in three very different products, and they're often discussed as if they were one. They aren't.

OTC cosmetic Copper Tripeptide-1: Sold over-the-counter as a cosmetic ingredient in serums, creams, and eye products. Regulated by the FDA as a cosmetic, not a drug. This is the form with the strongest human evidence. The 71-woman and 41-woman trials referenced above used cosmetic formulations.

Prescription compounded topical: Some 503A and 503B compounding pharmacies prepare custom-strength topical GHK-Cu under physician prescription. As of the FDA's April 22, 2026 503A bulks list update, GHK-Cu (non-injectable form) is being removed from Category 1 (Under Evaluation) because the original nominators withdrew their nominations. The FDA has stated it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 about whether GHK-Cu should be added to the formal 503A bulks list. Practically, this means compounded topical GHK-Cu sits in a regulatory transition window and supply may shift.

Research-use injectable: Sold by research peptide vendors as lyophilized powder. Injectable GHK-Cu is in 503A/503B Category 2 (significant safety concerns) and cannot legally be compounded for human injection. Vendors selling injectable GHK-Cu marketed for human use are operating outside the FDA's compounding framework. There is no FDA-approved injectable GHK-Cu drug product.

The closest comparator within the copper-peptide category is AHK-Cu (alanyl-histidyl-lysine-copper), a synthetic analogue that shows up in some hair-growth research. AHK-Cu was the active compound in the Pyo et al. 2007 dermal papilla study often cited as evidence for GHK-Cu's hair-growth potential. That is worth knowing, since the two are closely related but distinct molecules.

Outside the copper-peptide class, the most common comparators are signaling peptides like Matrixyl (Pal-KTTKS, used as a topical anti-wrinkle ingredient) and broader regenerative peptides like BPC-157 and TB-500. These compounds operate through entirely different mechanisms and are not interchangeable. Matrixyl is purely topical and targets collagen signaling; BPC-157 and TB-500 are research compounds with much more controversial regulatory and evidence profiles. A reader trying to decide between GHK-Cu and any of these should treat them as different research questions, not different products in the same category.